China’s cyber police probe ‘quasi-drug’ rumors aimed at major tea brand

What happened

China’s cyber police have investigated three cases of online rumor-mongering that labeled a well-known tea beverage brand as “quasi-drugs,” according to a report by IT Home (IT之家). The brand was not named. It has been reported that several social media posts alleged the chain’s drinks contained pharmacological or addictive ingredients and implied they were regulated like medicines. Police deemed the claims false, reportedly ordered posts removed, and took action against the accounts involved.

Why it matters

China’s “new tea” market—dominated by chains such as Heytea (喜茶), Nayuki (奈雪的茶), and Mixue Bingcheng (蜜雪冰城)—is fiercely competitive and highly sensitive to safety chatter. A viral allegation can dent sales and reputation within hours. The term “quasi-drug” is not a recognized classification for food and beverage products in mainland China, adding to confusion when such claims circulate. Platforms including Weibo (微博), Douyin (抖音), Xiaohongshu (小红书), and Baidu (百度) often face pressure to act quickly on fast-spreading posts that blur the line between consumer watchdogging and rumor.

The regulatory backdrop

The investigations fit a broader enforcement pattern under China’s Cybersecurity Law and the Provisions on the Governance of the Online Information Content Ecosystem, which target “malicious marketing,” disinformation, and traffic-seeking “self-media” accounts. Reportedly, the cases resulted in content takedowns and administrative penalties; further details were not disclosed. Authorities regularly urge users to “not fabricate, not spread” rumors—and warn that repeating unverified claims can draw sanctions, even if framed as questions.

The bigger picture

China’s policing of online speech has intensified around health, safety, and brand integrity, areas that can ignite public concern and market volatility. The episode underscores how quickly food-safety narratives can collide with information controls: How should genuine whistleblowing be distinguished from clickbait? For now, officials are signaling that allegations about product composition and regulatory status must be backed by evidence—or risk being treated as rumor.